Immunology in medical practice. VI. New immunosuppressive drugs;Immunologie in de medische praktijk. VI. Nieuwe immunosuppressieve geneesmiddelen

Nederlands Tijdschrift voor Geneeskunde

Volumn 141, Issue 47, 1997, Pages 2289-2292

  Ten Berge, R J M ^a   Schellekens, P Th A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BREQUINAR; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PURINE; RAPAMYCIN; TACROLIMUS;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL PRACTICE; REVIEW; SIGNAL TRANSDUCTION;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 0030776594     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis: preliminary report. Proc Staff Meet Mayo Clin 1949;24:181-97.
2. Schwartz RS, Stack J, Dameshek W. Effect of 6-mercaptopurine on antibody production. Proc Soc Exp Biol Med 1958;99:164-7.
3. Berge RJM ten, Schellekens PThA. Immunosuppressive drugs in clinical medicine. Neth J Med 1994;45:329-38.
4. Jeurissen MEC, Boerbooms AMTh, Putte LBA van de. Methotrexate therapy in connective tissue diseases a review of the literature. Neth J Med 1989;35:44-58.
5. Weinblatt ME. Methotrexate for chronic diseases in adults. New Engl J Med 1995;332:330-1.
6. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate Arthritis Rheum 1992;35:1322-9.
7. Cecka JM, Terasaki PI, Clinical transplants 1995. Los Angeles: UCLA.
8. Sartor RB. Cyclosporine therapy for inflammatory bowel disease. N Engl J Med 1994;330:1897-8.
9. Wells G, Tugwell P. Cyclosporin A in rheumatoid arthritis' overview and efficacy. Br J Rheumatol 1993;32 Suppl 1:51-6.
10. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, Kohsaka M, et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis Transplant Proc 1987;19(5 Suppl 6).4-8.
11. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T. et al. FK-506. a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987:40:1256-65.
12. Fung J, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Todo S, et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 1991; 23:2977-83.
13. Fung JJ, Todo S, Jain A, McCauley J, Alessiani M, Scotti C, et al. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine related complications. Transplant Proc 1990;22:6-12.
14. Fung J, Todo S. Abu-Elmagd K, Jain A, Tzakis A, Martin M, et al. Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. Transplant Proc 1993;25 (I Pt 2):1130.
15. Fung JJ, Todo S, Tzakis A, Demetris A, Jain A, Abu-Elmagd K, et al. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc 1991;23:14-21.
16. Shapiro R, Jordari J, Scantlebury V, Fung J, Jensen C, Tzakis A, et al. FK-506 in clinical kidney transplantation. Transplant Proc 1991; 23:3065-7.
17. Gjertson DW, Cecka MJ, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation 1995;60:1384-8
18. Japanese FK 506 Study Group. Japanese study of FK 506 in kidney transplantation. results of an early phase II study. Transplant Proc 1991;23:3071-4
19. Eugui EM, Almquist SJ, Muller CD, Allison AC, Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991;33:161-73.
20. Platz KP, Eckhoff D, Bechstein WO, Suzuki Y, Sollinger HW. RS-61443 for reversal of acute rejection in canine renal allografts. Surgery 1991;110:736-41.
21. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection Lancet 1995;345:1321-5
22. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group Transplantation 1995;60:225-32.
23. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61:1029-37.
24. Schiff MH, Goldblum R, Rees MMC. 2-Morpholinoethyl mycophenolic acid (ME-MPA) in the treatment of refractory rheumatoid artritis (RA). Arthritis Rheum 1990;33 s155
25. Calne RY, Collier DS, Lim S, Pollard SG, Samaan A, White DJ. et al. Rapamycin for immunosuppression in organ allografting Lancet 1989:2:227.
26. Lee HA, Slapak M, Venkatraman G, Mason J, Digard N, Wise M. Mizoribine as an alternative to azathioprine in triple-therapy immunosuppressant regimens in cadaveric renal transplantation Transplant Proc 1994;25:2699-700
27. Murphy MM, Morris RE. Brequinar sodium is a highly potent anti-metabolite immunosuppressant that suppresses heart allograft rejection. Med Sci Res 1991;19:835-6.
28. Bartlett RR, Campion G, Musikic R, Schleyerbach R, Zielinski T, Schorlemmer HU. Leflunomide: a novel immunomodulating drug In: Lewis AJ, First DE, editors. Non-steroidal anti-inflammatory drugs. New York: Dekker, 1994:349-66.